A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Kristina Holmegaard Nørskov
  • Katrine Fridthjof
  • Peter Kampmann
  • Anne Dünweber
  • Toni Renaberg
  • Claudia Schöllkopf
  • Syed Azhar Ahmad
  • Katrine Schou
  • Cecilie Fremming Jensen
  • Peter Møller
  • Birgitte Wolf Lundholm
  • Claus Marcher
  • Lene Jepsen
  • Anne Katrine Ørntoft
  • Hans Beier Ommen
  • Lotte Andersen
  • Anni Behrentzs
  • Connie Fruergaard Hasselgren
  • Marianne Severinsen
  • Lars Kjeldsen

Technological advances have made it possible to offer home-based chemotherapy to patients without health care professionals being present. Prior studies on effects of home-based treatment lack inclusion of patients with hematologic malignancies. We present data from a multicenter single-arm feasibility and safety study of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia and their quality of life and psychological wellbeing. This national study included patients from six sites in Denmark who received intensive chemotherapy on programmed CADD Solis infusion pumps through a central venous catheter and were also managed as outpatients during treatment-induced pancytopenia. Data are presented from 104 patients, receiving 272 treatments with 1.096 (mean 4.57, SD 3.0) home infusion days out of 1.644 treatment days (67 %). Sixty-two of 168 (36.9 %) reinduction and consolidation treatment cycles ensuing pancytopenia phases were solely handled in the outpatient clinic. Patients reported high satisfaction with home-based treatment, which had a positive influence on their ability to be involved in their treatment and be socially and physically active. No unexpected events occurred during the intervention. Overall, patients improved in all quality of life outcomes over time. Home-based intensive chemotherapy treatment was feasible and safe in this population. ClinicalTrials.gov identifier: NCT04904211.

TidsskriftLeukemia Research
Antal sider8
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
We are grateful to the patients who participated in this study. This study was funded by grants from the University Hospital of Copenhagen, Rigshospitalet, Denmark and TrygFonden (grant to KF and KHN).

Publisher Copyright:
© 2021 Elsevier Ltd

ID: 288777270